ArticleNature communications2026
Dual-stiffness nanoparticles for compartment-specific drug delivery in stroke.
Article in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- A pleiotropic single-molecule, sustained-release regenerative scaffold enables coordinated repair after ischemic stroke.Bioactive materials · 2026Article
- Targeted Retention of Cationic Liposomes at the Inflamed Blood-Brain Barrier by Incorporating Mesenchymal Stem Cell Membrane.Advanced healthcare materials · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
Abstract
Ischemic stroke presents a dual therapeutic challenge, involving dynamic and compartmentalized pathology in both the peripheral immune system and the central nervous system. Departing from conventional holistic treatment strategies, we developed a spatially tiered drug delivery approach using a combination of dual-stiffness nanoparticles (NPs) for compartment-specific therapy. Exploiting stiffness-dependent biodistribution, stiff NPs preferentially targeted peripheral immune cells, delivering anti-inflammatory agents to attenuate systemic inflammation and prevent immune cell infiltration into the brain. In parallel, soft NPs, shielded from immune uptake, efficiently penetrated the brain to deliver neuroprotectants and restore the damaged neural microenvironment. Mechanistic studies indicate that this selective distribution arises from the interplay between NP stiffness-dependent membrane energetics and competitive serum protein adsorption. This mechano-guided delivery strategy achieves synergistic "peripheral-central" intervention via a single administration, establishing a paradigm for precision nanomedicine, with broad potential in treating multi-compartment pathologies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.